☆ 4.6 Article

Population Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies

Guillermo Garcia-Manero et al.

Summary: This report reviews the potential use of orally bioavailable azacitidine (Oral-AZA) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and its unique pharmacokinetic and pharmacodynamic profile compared to injectable azacitidine. It also discusses the clinical safety and efficacy of Oral-AZA maintenance therapy in AML patients and for the treatment of patients with active MDS, as well as ongoing clinical trials.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Add to Collection

Article Oncology

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Farhad Ravandi et al.

Summary: Oral azacitidine maintenance therapy has shown favorable safety profile with common gastrointestinal and hematologic adverse events, rarely requiring permanent discontinuation. Prophylaxis with antiemetic agents and regular blood count monitoring are recommended for optimal management and treatment adherence.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

Hani M. Babiker et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

A. H. Wei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies

Michael R. Savona et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Oncology

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

G. Garcia-Manero et al.

LEUKEMIA (2016)

Add to Collection

Review Pharmacology & Pharmacy

Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia

Lesley J. Scott

DRUGS (2016)

Add to Collection

Article Multidisciplinary Sciences

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

Eric Laille et al.

PLOS ONE (2015)

Add to Collection

Article Pharmacology & Pharmacy

A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment

Eric Laille et al.

PHARMACOTHERAPY (2014)

Add to Collection

Article Hematology

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Josephine Aimiuwu et al.

BLOOD (2012)

Add to Collection

Article Oncology

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Guillermo Garcia-Manero et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

Carlo Stresemann et al.

INTERNATIONAL JOURNAL OF CANCER (2008)

Add to Collection

Article Oncology

Azacytidine causes complex DNA methylation responses in myeloid leukemia

Carlo Stresemann et al.

MOLECULAR CANCER THERAPEUTICS (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.